Psychedelic ETFs Back in the Spotlight
Psychedelic ETFs and Biotech and Genomics ETFs among Canada’s top weekly performers.

A psychedelic ETF reigned over Canada’s top-performing ETFs last week, driven by a positive stance by Morgan Stanley. Meanwhile, biotechnology and genomics-related ETFs benefit from strengthening select stocks.
Psychedelic ETF Reigns over this Week's Top Performers
The Horizons Psychedelic Stock Index ETF (PSYK) bested its Canadian exchange-traded funds, ranking first among the weekly top performers. PSYK has soared 17.27% during the first week of August as mainstream industry recognition continued apace. According to The Dales Report, the psychedelic sector has witnessed an upward trend since July 12th, 2022, when ‘How to Change Your Mind’ debuted on Netflix. Compass Pathways PLC, which happens to be the most significant holding of PSYK, was amongst the biggest beneficiaries of the trend, having risen around 61% in four weeks. Moreover, the company reported its financial results and business highlights, showing an increase in R&D expenditures and phase 3 program submission to the FDA. On another front, Counterpoint Global, Morgan Stanley’s investment management division in charge of understanding disruptive market opportunities, released a report focusing on psychedelics developments for medical purposes. The report pointed out Morgan Stanley’s positive stance on the psychedelics industry for the future. It predicts that the industry will grow to USD$6 trillion by 2030.
ETFs in play:
Biotech and Genomics ETFs in the Green
Some healthcare tech stocks experienced strengthening recently, pushing some Biotech and Genomics exchange-traded funds higher over the week between August 1st and August 5th. The Emerge ARK Genomics & Biotech ETF USD (EAGB.U) and CAD (EAGB), and the iShares Genomics Immunology and Healthcare Index ETF (XDNA), jumped 11.32%, 11.11%, and 8.16%, respectively. The gains were driven mainly by overlapping stocks trading in the green. Most notably, Beam Therapeutics Inc (NASDAQ:BEAM) rose 7.80% over the week to reach USD$63.63 while Fate Therapeutics Inc (NASDAQ:FATE) surged almost 11.25% – from USD$30.04 to USD$33.42 – over the same period. Together, these two stocks represent 9.1% of Emerge ARK Genomics & Biotech ETF’s total portfolio and 9.73% of iShares Genomics Immunology and Healthcare Index ETF.
ETFs in play:
Data for this article is as of August 5th, 2022.






